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Abstract  
Background & Aims Neoadjuvant chemoradiotherapy (NACRT) has increased local control in locally 
advanced rectal cancer. Reduced skeletal muscle mass (sarcopenia), or ongoing muscle wasting, is 
associated with decreased survival in cancer. This study aims to assess the change in body composition 
during NACRT and its impact on outcome using computed tomography (CT) imaging in locally advanced 
rectal cancer (LARC) patients. 
Methods LARC patients treated with NACRT were selected from a prospectively maintained database 
and retrospectively analyzed. One-hundred twenty-two patients who received treatment between 2004 
and 2012 with available diagnostic CT imaging obtained before and after NACRT were identified. Cross-
sectional areas for skeletal muscle was determined, and subsequently normalized for patient height. 
Differences between skeletal muscle areas before and after NACRT were computed, and their influence 
on overall and disease-free survival was assessed.  
Results A wide distribution in change of body composition was observed. Loss of skeletal muscle mass 
during chemoradiotherapy was independently associated with disease-free survival (HR0.971; 95% 
CI:0.946 – 0.996; p =0.025) and distant metastasis-free survival (HR0.942; 95% CI:0.898 – 0.988; p 
=0.013). No relation was observed with overall survival in the current cohort.  
Conclusions Loss of skeletal muscle mass during NACRT in rectal cancer patients is an independent 




Colorectal cancer is the third most common malignancy among male and second most common 
malignancy among female patients worldwide. [1] It is a leading cause of cancer death in more 
developed countries. Rectal cancer accounts for up to 30% of all colorectal malignancies. For patients 
with locally advanced rectal cancer, neoadjuvant chemoradiotherapy (NACRT) combined with total 
mesorectal excision (TME) is considered best available treatment. [2, 3]  
Recently, sarcopenia (muscle wasting) has been described as a potent prognostic marker in 
gastrointestinal and hepatopancreatobiliary malignancies. [4-15] Sarcopenic patients, i.e. patients with a 
lesser quantity of muscle mass, have an increased risk for early death. Age, cancer cachexia and 
oncological treatment may contribute to this state of low muscle mass. [16-18] Interestingly, NARCT 
itself has been reported to reduce skeletal muscle mass in esophagogastric cancer patients. [16] Another 
study confirmed these findings, and furthermore showed that greater loss of muscle mass during 
neoadjuvant treatment is associated with an increased risk of postoperative mortality. [19] Likewise, in 
non-resectable colorectal cancer patients, skeletal muscle loss after systemic chemotherapy is an 
independent, negative prognostic factor. [20] Interventions to stop or even reverse progressive muscle 
wasting in patients undergoing potentially curative anti-cancer therapy are currently being investigated 
and would, if found, provide new strategies in the management of cancer patients. 
To this moment, the impact of NACRT on body composition in patients with locally advanced rectal 
cancer (LARC) has not yet been described. Therefore, in the current study we aim to (1) investigate 
whether NACRT induces a change in body composition in LARC patients, (2) assess the impact of change 
in body composition during NACRT on outcome (i.e. short-term outcome, overall survival, disease-free 
survival, and development of distant metastases).   
Methods  
Patients 
All histologically confirmed, LARC patients who underwent NACRT and TME in the Erasmus MC Cancer 
Institute, a tertiary referral center in the Netherlands for locally advanced and stage IV colorectal cancer, 
between August 2004 and December 2012 289 patients were enrolled in a prospectively maintained 
database and retrospectively analyzed. The study protocol was approved by medical ethical committee 
of the Erasmus MC, University Medical Center, Rotterdam, The Netherlands (MEC-2017-239). LARC 
was defined as T3 or T4 rectal tumors (i.e. tumors located ≤ 15 cm of the anal verge as determined by 
MRI and colonoscopy) with clinical suspicion of narrow or involved circumferential resection margins 
(CRM) with or without potentially malignant lymph nodes, or rectal tumors with potentially malignant 
lymph nodes outside the TME plane, as previously described. [21] Collected data included details on 
patient age, gender, body-mass index (BMI), comorbidities, cancer stage, carcinoembryonic antigen 
(CEA), surgical and chemoradiotherapeutic treatment, clinical response rate, recurrence and survival. 
From the initial 289 patients, 122 patients received abdominal computed tomography (CT) imaging 
before standardized preoperative chemoradiotherapy (preCRT), and a restaging CT scan (postCRT) to 
identify any possible previously non-detectable distant metastases, according to local protocol. [22] 
Only patients with adequate preCRT and postCRT scans were considered eligible for inclusion in the 
current study.  
 
Preoperative chemoradiotherapy and surgical resection 
All patients received preoperative chemoradiation therapy as a long course (50 Gy) delivered in 25 
fractions in accordance to the Dutch guidelines, i.e. chemoradiotherapy for rectal cancer classified as 
LARC. Capecitabine (825 mg/m2) was administered orally twice a day during radiotherapy days, and 
radiotherapy was administered via a three-field technique, using one posterior and two lateral portals, a 
four-field box or with five fields using intensity modulated radiotherapy. [23] 
TME was performed after completing chemoradiation, if considered eligible for resection. A midline 
laparotomy was carried out in all patients. A primary anastomosis was performed whenever possible. A 
diverting ileostomy was created at the discretion of the treating physician. In T4 tumors involving the 
sphincter apparatus after NACRT, an abdominoperineal resection was performed. In T4 tumors involving 
adjacent structures after NACRT (e.g. prostate, uterus, bladder) these were resected simultaneously. 
Intraoperative radiotherapy was applied if the circumferential resection margin (CRM, ≤ 2 mm) was 
considered to be at risk. [24] 
 
Postoperative follow-up 
Patients follow up was done on an outpatient basis by periodic six months CT imaging or abdominal 
ultrasonography during the first two postoperative years, followed by yearly imaging for the remainder 
of the follow-up. Serum CEA determination was done at intervals of three to six months during the first 
three years of follow-up, and subsequently every six months during the final years of follow-up. Patients 
were followed up for at least 5 years in case of no recurrence. None of the patients were treated with 
adjuvant chemotherapy according to the Dutch guidelines. The national civil registry was consulted for 
definitive survival data. 
 
Assessment of body composition 
Body composition was measured on standard diagnostic CT scans with FatSeg version 4.0 (Erasmus MC – 
BIGR, Rotterdam, Netherlands). Cross-sectional areas (cm2) of skeletal muscle mass was measured at the 
level of the third lumbar vertebrae as previously described. [15] 
 
Statistical analysis 
Continuous data are presented as mean ± SD or median (IQR) as appropriate. Categorical data are 
presented as number counts and percentages. The Student’s t-test was used for assessment of 
differences between groups for continuous variables. The χ2 or Fisher’s exact test was used for 
assessment of differences between groups for categorical variables where appropriate. Skeletal muscle 
mass was normalized for patient height (skeletal muscle index [SMI]). Paired t-test was used for the 
between group comparisons of continuous variables for SMI on preCRT and postCRT scans. Relative 
change in cross-sectional areas (Δ CSA = postCRT / preCRT) were computed for SMI. Gender specific 
tertiles were determined for Δ SMI. Overall and disease-free survival rates were calculated using the 
non-parametric Kaplan–Meier method and subsequently compared with the log rank test. Univariate 
and multi-variable Cox regression analyses were performed to investigate the association between Δ 
SMI and survival. Hazard Ratios (HR) with 95% confidence intervals (95% CI) were computed. 
Furthermore, age, gender, diabetes, BMI, tumor location, CEA, surgical procedure, intraoperative 
radiotherapy, pathologic T-, N- and M- stage, circumferential resection margin, and pathologic complete 
response were included in the univariate Cox regression analysis. These variables were checked for 
interaction and confounding. They were subsequently included in the multivariable model if a p-value < 
0.05 was found in univariate analysis.  
All statistical analyses were performed using SPSS version 21.0 (SPSS, Chicago, Illinois, USA). A p-value < 
0.05 was considered statistically significant. 
Results 
Clinical characteristics and body composition 
One hundred and twenty-two patients, with a median follow-up of 41 months (IQR 26 – 62) were 
eligible for inclusion (Table 1). During the follow-up period, 50 (41.0%) patients developed recurrent or 
metastatic disease, and 35 patients (28.7%) died. Forty (32.8%) patients had metastatic disease at onset 
of NACRT. Twenty-nine (23.8%) patients were treated by liver first approach. [25, 26] Eleven patients 
underwent synchronous resection. In the studied population, median length of hospital stay was 8 (IQR: 
7 – 11) days. 
Abdominal CT-imaging was obtained at median 48 (IQR: 35 – 65) days prior to onset of NACRT. 
Restaging scans were obtained at a 28 (IQR: 21.5 – 39.5) days after completion of NACRT. Following 
NACRT, mean skeletal muscle index (SMI) remained unchanged. Despite minimal changes in the mean 
SMI, a wide distribution in change of body composition was observed.  
 
Loss of muscle mass and disease stage 
After NACRT, lower SMI was found in patients with cT4 tumours when compared to patients with cT3 
tumours (48.1 ± 8.3 versus 44.7 ± 8.2, p = 0.024). No association between clinical disease stage and Δ 
SMI was observed. 
For analytical purposes, gender-specific tertiles for Δ SMI were created (< -1.95%; -1.95% – 1.84%; > 
1.84% for male patients and < -4.53%; -4.53% –  1.90%; > 1.90% for female patients). Comparing 
patients in the obtained tertiles for Δ SMI, no differences in patient demographic and clinical 
characteristics (i.e. age, gender, BMI, clinical TNM staging, CEA, tumor height, surgical procedure, and 
IORT), pathologic TNM staging, pathologic CRM, and pathologic complete response were observed. 
There was a weak negative relationship between pre-NACRT SMI and Δ SMI (Pearson’s r: -0.254; p = 
0.005), i.e. patients with a higher quantity of muscle mass prior to NACRT experienced greater loss of 
muscle mass. Vaso-invasion was present in 10 (31.2%) patients in the lower tertile, 3 (8.8%) in the 
middle tertile, and in 3 (9.4%) patients in the upper tertile for Δ SMI respectively (p = 0.021).  
 
Overall survival 
The one-, three-, and five-year overall survival (OS) rates in the current cohort were 93%, 77%, and 69% 
respectively. A median survival time was not reached. Patients in the lower tertile for Δ SMI had one-, 
three-, and five-year OS rates of 95%, 68%, and 68% respectively; patients in the middle tertile for Δ SMI 
had one-, three-, and five-year OS rates of 95%, 82%, and 65%; and patients in the higher tertile for Δ 
SMI had one-, three-, and five-year OS rates of 90%, 80%, and 74% (Figure 1, log-rank p = 0.520). 
Additionally, gender-specific cut-off values for sarcopenia as previously reported in literature were 
investigated for their impact on overall survival. [17] No association could be found between sarcopenia 
pre-operatively (i.e. using the post-NACRT CT scan) and OS (HR: 1.313; 95% CI: 0.675 – 2.551; p = 0.422) 
or sarcopenia pre-NACRT and OS (HR 1.183; 95% CI: 0.607 – 2.305; p = 0.621).  
 
Disease-free survival 
The one-, two-, and three- -year disease-free survival (DFS) rates were 72%, 62%, and 57% respectively. 
Eight (6.6%) patients developed local recurrence, and 46 (37.7%) patients developed distant metastases. 
A median DFS time was not reached. An association was observed between Δ SMI and DFS in log-rank 
analysis (Figure 2) and in multivariable analysis (HR 0.971; 95% CI: 0.946 – 0.996; p = 0.025). Moreover, 
analysis of patients without evidence of metastatic disease at presentation revealed that Δ SMI was an 
independent predictor for the development of distant metastases following curative intent treatment in 
multivariable Cox-regression analysis (HR 0.942; 95% CI: 0.898 – 0.988; p = 0.013) (Table 3). The one-, 
three-, and five-year DMFS rates were 74%, 51%, and 51% respectively for patients in the lowest tertile 
for Δ SMI, compared with 77%, 73%, and 73% respectively for patients in the middle tertile for Δ SMI, 
and 100%, 92%, and 85% respectively for patients in the upper tertile for Δ SMI (Figure 3).  
There was no association between pre-operative sarcopenia and DFS using pre-defined cut-off values 
(HR: 1.153; 95% CI: 0.662 – 2.009; p = 0.615). Likewise, there was no association between pre-NACRT 





This study describes the change in body composition which may be observed in patients undergoing 
NACRT for locally advanced rectal cancer. This is the first study to show that loss of muscle mass during 
NACRT, assessed by use of routinely obtained diagnostic CT images, has a strong association with 
disease-free survival and distant metastasis-free survival. This technique is inexpensive, readily 
available, and may thus help identify patients at risk for detrimental outcome.  The results of this study 
may be used to determine inclusion criteria for future clinical studies investigating treatment regiments 
aimed at stopping or reversing muscle loss in cancer patients, as well as for future clinical studies 
investigating follow-up regiments following curative intent rectal cancer surgery. 
A wide variation was observed in the amount of muscle loss during NACRT. As such, tumor biology 
rather than NACRT per se is more likely to be the causative factor inducing this catabolic state. Opposed 
to what we expected, we did not observe any association between disease-stage and the amount of 
muscle loss during NACRT. However, we did observe an association between vascular invasion and 
muscle loss during NACRT. Colorectal cancer is known to be associated with different molecular 
subtypes, with no association to TNM staging. [27] Select molecular subtypes may be associated with a 
more aggressive tumor biology and stronger systemic catabolic response. A study investigating the 
association between colorectal cancer genotyping and muscle wasting is currently being undertaken by 
our research group.  
Skeletal muscle loss during NACRT was associated with poor disease-free survival, and a higher risk of 
developing distant metastasis during follow-up in the current population. These findings are in line with 
prior literature on esophageal cancer and non-resectable colorectal cancer patients. [19, 20] Another 
study showed that loss of muscle mass during NACRT is associated with increased postoperative 
mortality following surgical resection for esophageal cancer. [19] Yet another study reported non-
resectable colorectal cancer patients receiving systemic therapy to have a reduction in both progression-
free survival and overall survival if skeletal muscle loss was observed during treatment. [20] While loss 
of muscle mass during NACRT was strongly associated with DFS and DMFS, single time point 
measurements for sarcopenia that are widely used were not predictive of survival in the current 
population.  
Despite mounting evidence for sarcopenia and muscle wasting to be associated with poor survival and 
decreased quality of life [28, 29], it is still unknown whether targeted treatment of muscle wasting may 
improve outcome. Over the past decade our understanding of muscle wasting in cancer has greatly 
increased [30, 31], and has led to the initiation of clinical trials investigating interventional strategies 
aimed at halting or reversing cancer related muscle wasting. [32-35] Whether these treatment regimens 
are efficacious remains to be answered, but if so the interval between chemoradiotherapy and surgery 
might offer a perfect window of opportunity to improve the overall condition of LARC patients. 
There are several limitations to this present study, some of which have already been described. 
Information regarding change of bodyweight was not gathered routinely in this cohort. Furthermore, 
information regarding possible lack of appetite, anorexia, was not available on a consistent basis. 
Likewise, no information regarding physical status and performance was available for these patients. 
Lastly, although suggestively differences in tumor biology may explain the findings reported within this 
study, validating this hypothesis was not within the scope of the current study. Data regarding vaso-
invasion, perineural growth, and lymphoinvasion was missing for a considerable number of patients. 




This study found loss of skeletal muscle mass during, but not necessarily attributable to, neoadjuvant 
chemoradiotherapy in resectable rectal cancer patients to be a novel independent prognostic factor for 
disease-free survival and distant metastasis-free survival following total mesorectal excision. This 
knowledge may benefit in patient expectation management following curative intent treatment, as well 
as provide grounds for future clinical studies investigating whether there may be a role for adjuvant 
therapy in patients showing greatest loss of muscle mass, i.e. who were found to have the highest rate 
of metastasis development.   
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Table 1. Baseline Demographic and Clinical characteristics of the 122 Patients Included in the Study 
Table 1. Baseline Demographic and Clinical Characteristics of the 122 Patients Included in the Study 
  Number of patients Median (IQR) 
Age (years)   61 (53.0 – 66.3) 
Gender (M : F)  71 : 51 (58.2% : 41.8%)  
Cardiac comorbidity (excluding hypertension)  10 (8.2%)  
Respiratory comorbidity  19 (15.6%)  
Diabetes  14 (11.5%)  
BMI (kg/m2)*   24.3 (22.0 – 26.8) 
Tumor location (cm)* < 6 60 (49.6%)  
 ≥ 6 61 (50.4%)  
CEA (ng/mL)* < 5 32 (43.2%)  
 ≥ 5 42 (56.8%)  
Clinical T-stage* T3 65 (53.7%)  
 T4 56 (46.3%)  
Clinical N-stage* N- 25 (20.7%)  
 N+ 96 (79.3%)  
Clinical M-stage* M0 82 (67.2%)  
 M1 40 (32.8%)  
Time interval between NACRT and resection (days)   70 (62.5 – 84.5) 
Pathologic T-stage* ypT0 25 (20.7%)  
 ypT1 4 (3.3%)  
 ypT2 16 (13.2%)  
 ypT3 52 (43.0%)  
 ypT4 24 (19.8%)  
Pathologic N-stage* ypN0 84 (69.4%)  
 ypN1 25 (20.7%)  
 ypN2 12 (9.9%)  
Pathologic M-stage ypM0 83 (68.0%)  
 ypM1 39 (32.0%)  
CRM R0 100 (82.0%)  
 R1 20 (16.4%)  
 R2 2 (1.6%)  
Vaso-invasion* No 82 (83.7%)  
 Yes 16 (16.3%)  
Perineural growth* No 82 (83.7%)  
 Yes 16 (16.3%)  
Lymphoinvasion* No 60 (95.2%)  
 Yes 3 (4.8%)  
Surgical procedure  (all open procedures) LAR 45 (36.9%)  
 APR 45 (36.9%)  
 Pelvic 
exenteration 
32 (26.2)  
Intraoperative radiotherapy  16 (13.1%)  
SMI pre-NACRT (cm2/m2)   46.6 (41.2 – 53.4) 
SMI post-NACRT (cm2/m2)   46.9 (40.2 – 53.1) 
*Data missing for some patients. M : F: Male : Female. BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal 
muscle index assessed at the third lumbar vertebrae, and standardized for patient height. NACRT: Neo-adjuvant 
chemoradiotherapy. CRM Circumferential resection margin, an R1 resection was defined as a circumferential resection margin < 
2mm. 
Table 2. Univariate and Multivariate Cox Regression Analysis for Disease-Free Survival 
 Univariate analysis Multivariable analysis Hazard Ratio P Hazard Ratio P 
Gender Male 1.00 (reference)    
 Female 1.04 [0.59 – 1.81] 0.899   
Age  Per year 0.98 [0.96 – 1.00] 0.089   
Diabetes No 1.00 (reference)    
 Yes 0.52 [0.16 – 1.68] 0.278   
Δ SMI Per 1% change 0.96 [0.94 – 0.99] 0.004 0.97 [0.95 – 1.00] 0.025 
BMI  Per kg/m2 1.04 [0.97 – 1.12] 0.238   
Tumor location (cm) < 6 1.00 (reference)    
 ≥ 6 0.85 [0.48 – 1.48] 0.557   
CEA (ng/mL) < 5 1.00 (reference)    
 ≥ 5 1.56 [0.76 – 3.20] 0.223   
Surgical procedure  LAR 1.00 (reference)    
 APR 1.38 [0.71 – 2.70] 0.342   
 Pelvic exenteration 1.79 [0.87 – 3.67] 0.111   
Intraoperative radiotherapy No 1.00 (reference)    
 Yes 2.11 [1.05 – 4.22] 0.035 1.44 [0.47 – 4.39] 0.523 
Pathologic T-stage ypT0 – ypT3 1.00 (reference)    
 ypT4 2.10 [1.13 – 3.89] 0.019 1.23 [0.56 – 2.71] 0.608 
Pathologic N-stage ypN0 1.00 (reference)    
 ypN1 or ypN2 2.44 [1.38 – 4.30] 0.002 1.85 [1.01 – 3.40] 0.047 
CRM R0 1.00 (reference)    
 R1 or R2 2.19 [1.17 – 4.13] 0.015 1.04 [0.37 – 2.94] 0.944 
PCR Yes 1.00 (reference)    
 No 3.72 [1.34 – 10.35] 0.012 2.75 [0.92 – 8.20] 0.069 
BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal muscle index assessed at the third lumbar vertebrae, and 
standardized for patient height. NACRT: Neo-adjuvant chemoradiotherapy. CRM Circumferential resection margin. PCR 
Pathological complete response. 
 
Table 3. Univariate and Multivariate Cox Regression Analysis for Distant Metastasis-Free Survival in 
Patients without Evidence of Metastatic Disease at Presentation 
 Univariate analysis Multivariable analysis Hazard Ratio P Hazard Ratio P 
Gender Male 1.00 (reference)    
 Female 1.38 [0.58 – 3.27] 0.469   
Age  Per year 0.98 [0.95 – 1.02] 0.274   
Diabetes No 1.00 (reference)    
 Yes 0.04 [0.00 – 21.38] 0.319   
Δ SMI Per 1% change 0.93 [0.88 – 0.98] 0.007 0.94 [0.90 – 0.99] 0.013 
BMI  Per kg/m2 1.10 [0.99 – 1.22] 0.084   
Tumor location (cm) < 6 1.00 (reference)    
 ≥ 6 0.42 [0.16 – 1.09] 0.073   
CEA (ng/mL) < 5 1.00 (reference)    
 ≥ 5 1.31 [0.42 – 4.10] 0.638   
Surgical procedure  LAR 1.00 (reference)    
 APR 1.80 [0.60 – 5. 37] 0.294   
 Pelvic exenteration 2.09 [0.66 – 6.60] 0.209   
Intraoperative radiotherapy No 1.00 (reference)    
 Yes 2.61 [0.96 – 7.14] 0.061   
Pathologic T-stage ypT0 – ypT3 1.00 (reference)    
 ypT4 1.90 [0. 73 – 4.89] 0.186   
Pathologic N-stage ypN0 1.00 (reference)    
 ypN1 or ypN2 3.68 [1.56 – 8.69] 0.003 3.49 [1.46 – 8.35] 0.005 
CRM R0 1.00 (reference)    
 R1 or R2 2.32 [0.90 – 5.98] 0.082   
PCR Yes 1.00 (reference)    
 No 29.94 [0.37 – 2424.34] 0.129   
BMI: Body-mass index. CEA: Carcinoembryonic antigen. SMI: Skeletal muscle index assessed at the third lumbar vertebrae, and 
standardized for patient height. NACRT: Neo-adjuvant chemoradiotherapy. CRM Circumferential resection margin. PCR 
Pathological complete response. 
  
Figure 1. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy does not affect overall 
survival in rectal patients following surgical resection (log rank test p = 0.520).  
 
  
Figure 2. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy is associated with 
impaired disease-free survival in rectal cancer patients following surgical resection (log-rank p = 0.027).  
 
  
Figure 3. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy is associated with the 
development of distant metastases following curative intent treatment in patients without evidence of 
metastatic disease at presentation (log-rank p = 0.009). 
 
 
 
 
